Results 11 to 20 of about 39,529 (215)

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source

Characterizing the delays in adequate thromboprophylaxis after TBI

Trauma Surgery & Acute Care Open, 2021
Background We sought to compare enoxaparin dosing for venous thromboembolism (VTE) prophylaxis in trauma patients with and without traumatic brain injury (TBI) to better understand the time and dose required to reach target anti-Xa levels. Our hypothesis
Eric J Ley, Navpreet K Dhillon, Yassar M Hashim, Naomi Berezin, Felix Yong, Geena Conde, Russell Mason   +6 more
doaj   +1 more source

Critically ill patients with edema and ascites may experience subtherapeutic anti-factor Xa levels following abdominal subcutaneous enoxaparin treatment

SAGE Open Medical Case Reports, 2022
Enoxaparin is a low molecular weight heparin that is principally prescribed for the treatment and prevention of thromboembolic disorders. In clinical practice, the abdominal site for subcutaneous enoxaparin administration is most preferable because of ...
Vichapat Tharanon, Theerasuk Kawamatawong   +1 more
doaj   +1 more source

Cancer and thrombosis: Managing the risks and approaches to thromboprophylaxis [PDF]

, 2006
Patients with cancer are at increased risk of venous thromboembolism (VTE) compared with patients without cancer. This results from both the prothrombotic effects of the cancer itself and iatrogenic factors, such as chemotherapy, radiotherapy, indwelling
Altinbas M, Athanasoulis CA, Bergqvist D, Bergqvist D, Buller HR, Clagett PG, Da Silva MS, Decousus H, ENOXACAN Study Group, Falanga A, Geerts WH, Gitter MJ, Goldenberg N, Gomes MPV, Green D, Haas S, Heit JA, Hettiarachchi RJK, Hull R, Hutten BA, International Multicentre Trial, Johnson MJ, Kakkar VV, Karthaus M, Koopman MMW, Levine MN, Mousa S A, Mousa SA, Prandoni P, Rasmussen MS, Rickles FR, Sallah S, Samama M, Siragusa B, The Columbus Investigators, White RH, Zacharski LR   +36 more
core   +1 more source

How we treat bleeding associated with direct oral anticoagulants [PDF]

, 2016
Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo, Liumbruno, Giancarlo M, Marano, Giuseppe, Pupella, Simonetta, VAGLIO, Stefania   +4 more
core   +1 more source

Dosis Efektif Enoxaparin dalam Mencegah Terjadinya Trombosis pada Anastomosis Arteri Femoralis Tikus

JBN (Jurnal Bedah Nasional), 2017
Tujuan: untuk mengetahui dosis efektif enoxaparin dalam mencegah terjadinya trombosis pada anastomosis mikrovaskular. Metode: penelitian ini bersifat eksperimental dengan rancangan the randomized post test only control group design.
I Made Suka Adnyana, Iswinarno Doso Saputro   +1 more
doaj   +1 more source

Where and when to inject low molecular weight heparin in hemodiafiltration? : a cross over randomised trial [PDF]

, 2015
Background and Objective : Low molecular weight heparins (LMWHs) are small enough to pass large pore dialysis membranes. Removal of LMWH if injected before the start of the session is possible during high-flux dialysis and hemodiafiltration.
Devreese, Katrien, Dhondt, Annemieke, Eloot, Sunny, Glorieux, Griet, Pauwels, Ruben, Vanholder, Raymond   +5 more
core   +3 more sources

Enoxaparin-induced reactive thrombocytosis: a case report

Thrombosis Journal, 2021
Background Enoxaparin is an anticoagulant that falls in the class of medications called low molecular weight heparins (LMWHs), and is used to prevent or treat patients with deep vein thrombosis (DVT) and pulmonary embolism.
Tao Xiang, Ming Cheng
doaj   +1 more source

Micro-computed tomography for the quantification of blocked fibers in hemodialyzers [PDF]

, 2018
A novel technique based on micro-CT scanning is developed to quantify coagulation in fibers of hemodialyzers. This objectivation is needed to allow accurate assessment of thrombogenicity of dialyzers used during hemodialysis, for example when comparing ...
Boone, Matthieu, Dhondt, Annemieke, Dierick, Manuel, Eloot, Sunny, Van Biesen, Wim, Vanommeslaeghe, Floris   +5 more
core   +2 more sources

Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in Low Body Weight Patients

Clinical Medicine Insights: Blood Disorders, 2019
Background: The appropriate dose of enoxaparin for venous thromboembolism (VTE) prophylaxis in low body weight patients is unknown. Objective: The aim of this study is to evaluate the impact of enoxaparin dosing on major and minor bleeding events in low ...
Daniel Dybdahl, Grant Walliser, Michelle Pershing, Christy Collins, David Robinson   +4 more
doaj   +1 more source